Minimus Spine is privately held. To date, the company has been funded by angel investors and the State of Texas.
Minimus Spine has an experienced management team that has successfully developed the product, secured patent protection, and received the necessary certifications to commercialize the product in Europe. The company is currently enrolling a post-market European study comparing clinical outcomes in patients randomized between Triojection and discectomy. With these data, Minimus Spine is making plans to begin commercial activities in Europe.
Accredited Investors (as defined in the US Securities Act of 1933, Rule 501 of Reg D) may contact Dr. David Hooper to discuss investment opportunities.